Abstract
No public abstract is available from the verified source records.
Kyle P. Gribbin, Hen Halamish, Ivan Rodriguez Siordia, Jennifer M. Finan, Michael J. Pishvaian, Charles D. Lopez, Adel Kardosh, Shaun Goodyear, Rosalie C. Sears, Teresa Zimmers, Aaron Grossberg, Katelyn T. Byrne, Jonathan R. Brody
Abstract
Authors
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers
10.1158/2159-8290.cd-24-0027 · 2024
Cancer interception with KRAS inhibitors in preclinical models of pancreatic ductal adenocarcinoma
10.1126/science.aec7929 · 2026
Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer
10.1056/nejmoa2605555 · 2026
Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq Trial-ECOG-ACRIN EA6134
10.1200/jco.22.01763 · 2023
Altered gemcitabine and nab-paclitaxel scheduling improves therapeutic efficacy compared to standard concurrent treatment in pre-clinical models of pancreatic cancer
10.1158/1078-0432.ccr-20-1422 · 2021
Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer
10.1126/science.1171362 · 2009
Endpoints for mouse abdominal tumor models: refinement of current criteria
2009
Ras signals principally via Erk in G1 but cooperates with PI3K/Akt for Cyclin D induction and S-phase entry
10.1080/15384101.2018.1560205 · 2019
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No additional external references are available.